You are here: Industry Insights > depression

News List

Allergan's rapastinel fails to hit key targets in depression trials pharmatimes
March 08, 2019
Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.
Johnson & Johnson's Spravato garners FDA approval for treatment-resistant depression firstwordpharma
March 06, 2019
The FDA announced the approval of Johnson & Johnson's Spravato (esketamine), in conjunction with an oral antidepressant, for adults with treatment-resistant depression.
Contributors to Delay of Multiple Sclerosis Diagnosis ID'd drugs
February 27, 2019
First symptoms and disease type are contributors to delays in multiple sclerosis (MS) diagnosis, according to a study recently published in the Multiple Sclerosis Journal.....
FDA panel supports Janssen’s esketamine nasal spray for depression pharmaceutical-technology
February 14, 2019
Janssen Pharmaceutical has secured recommendation from the US Food and Drug Administration (FDA) advisory committees for the approval of its esketamine nasal spray Spravato to treat adults with treatment-resistant depression.
Objectively Assessed Exercise Protective Against Depression drugs
January 24, 2019
Objectively assessed physical activity is associated with a protective relationship with major depressive disorder (MDD), according to a study published online Jan. 23 in JAMA Psychiatry.....
NICE backs digital CBT for youngsters with depression pharmaphorum
January 24, 2019
NICE has recommended digital cognitive behavioural therapy (CBT) should be used as a first-line treatment for children and young people with mild depression.
Assessing Symptoms After 4 Weeks of Psychotherapy Helpful in Teens drugs
January 22, 2019
Therapists implementing interpersonal psychotherapy for depressed adolescents (IPT-A) should routinely monitor depression symptoms and consider augmenting treatment for insufficient responders as early as week 4 of treatment....
Magnetic therapy developer Brainsway files for $30M Nasdaq IPO fiercebiotech
January 17, 2019
Brainsway, developer of magnetic device treatments for depression and obsessive-compulsive disorder, plans to raise $30 million through an initial public offering on the Nasdaq under the symbol “BWAY.”...
Recalling Positive Memories May Cut Depression Risk for Teens drugs
January 16, 2019
Recalling specific positive life experiences may build resilience and help lower vulnerability to depression among adolescents with a history of early-life stress....
Simple Treatments to Banish Winter Blues drugs
January 16, 2019
The gray days of winter bring many people down, but a few simple steps can pep you up, an expert says.A condition known as seasonal affective disorder (SAD) can cause feelings of ....

Previous page 1 2 3 4 5 6 7 8 9 10 Next page